Since the discovery of kanamycin in 1957,1this antibiotic has been used clinically in conditions often treated with streptomycin or neomycin. Histopathologic evidence of ototoxicity2-6similar to that seen from streptomycin and neomycin, and a lack of cochlear microphonic response and of Cr. VIII nerve action potentials2have been reported in kanamycin toxicity. Comparison of cochlear microphonics between kanamycin-damaged and dihydrostreptomycin-damaged ears showed a much greater depression of response in patients demonstrating kanamycin in the serum 24 hours after the original injection. The histopathological changes reported were atrophy of the organ of Corti and a reduction of spiral ganglion cell population. Kanamycin B was found to be much more toxic than the original kanamycin.2Typical concentrations of kanamycin used by previous investigators are as follows: Hawkins: 50 mg. per kilogram for 75 days; 200 mg. per kilogram for 30, 50, 70, 75 days. Owada: 250 mg.